| P2093 | author name string | Zhe-Sheng Chen | |
| | Dong-Hua Yang | |
| | Yihang Pan | |
| | Ning Ji | |
| | Jonathan Y Li | |
| | Zi-Ning Lei | |
| | Qingbin Cui | |
| | Leli Zeng | |
| | Jing-Quan Wang | |
| | Qiu-Xu Teng | |
| P2860 | cites work | A multidrug resistance transporter from human MCF-7 breast cancer cells | Q22008574 |
| | Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer | Q24307748 |
| | Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy | Q24635408 |
| | AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading | Q27860652 |
| | Mitotane Enhances Cytotoxicity of Chemotherapy in Cell Lines Expressing a Multidrug Resistance Gene (mdr-1/P-Glycoprotein) which is also Expressed by Adrenocortical Carcinomas | Q28322699 |
| | Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells | Q32016277 |
| | Localization of the placental BCRP/ABCG2 transporter to lipid rafts: Role for cholesterol in mediating efflux activity | Q32174706 |
| | Induction of apoptosis by cancer chemotherapy. | Q33876771 |
| | Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs | Q34060806 |
| | Transport of molecules across tumor vasculature | Q34174488 |
| | Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. | Q34803651 |
| | ABC-transporters: implications on drug resistance from microorganisms to human cancers | Q35295622 |
| | Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells | Q35762594 |
| | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | Q35958056 |
| | Role of the breast cancer resistance protein (ABCG2) in drug transport | Q36250753 |
| | Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. | Q37148461 |
| | The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade | Q38305824 |
| | Venetoclax: First Global Approval | Q38853500 |
| | Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines | Q38909188 |
| | Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP). | Q39051270 |
| | Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse | Q40281717 |
| | Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. | Q40453744 |
| | Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). | Q40460067 |
| | Human breast cancer resistance protein: interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. | Q40516084 |
| | Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing binding | Q40556790 |
| | Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. | Q40707113 |
| | Structure of the human multidrug transporter ABCG2. | Q41597764 |
| | Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin | Q42438441 |
| | The nature of amino acid 482 of human ABCG2 affects substrate transport and ATP hydrolysis but not substrate binding | Q42497704 |
| | Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells. | Q43739398 |
| | Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells | Q43786282 |
| | Reversal of breast cancer resistance protein (BCRP/ABCG2)‐mediated drug resistance by novobiocin, a coumermycin antibiotic | Q44656390 |
| | The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. | Q44907485 |
| | Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype | Q44960521 |
| | Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies | Q47139045 |
| | Structure activity relationships, multidrug resistance reversal and selectivity of heteroarylphenyl ABCG2 inhibitors | Q48510774 |
| | Clinically relevant interactions of anti-apoptotic Bcl-2 protein inhibitors with ABC transporters. | Q50018089 |
| | Revisiting the role of ABC transporters in multidrug-resistant cancer. | Q52593092 |
| | Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. | Q54419426 |
| | Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells | Q57477828 |
| | Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells | Q57816977 |
| | VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters | Q58697844 |
| | Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 |
| | Ciprofloxacin Enhances the Chemosensitivity of Cancer Cells to ABCB1 Substrates | Q61796363 |
| | The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2) | Q73777786 |
| | Structural basis of small-molecule inhibition of human multidrug transporter ABCG2 | Q88249559 |
| | Discovery of 5-Cyano-6-phenylpyrimidin Derivatives Containing an Acylurea Moiety as Orally Bioavailable Reversal Agents against P-Glycoprotein-Mediated Mutidrug Resistance | Q89429562 |
| | Midostaurin Reverses ABCB1-Mediated Multidrug Resistance, an in vitro Study | Q91644097 |
| | Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression | Q91692891 |
| | Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance | Q91856055 |
| | ABC transporters as cancer drivers: Potential functions in cancer development | Q91882907 |
| | Gaseous signaling molecules and their application in resistant cancer treatment: from invisible to visible | Q91889048 |
| | Tepotinib reverses ABCB1-mediated multidrug resistance in cancer cells | Q91948322 |
| | Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells | Q92825248 |
| | Derivative of 5-cyano-6-phenylpyrimidin antagonizes ABCB1- and ABCG2-mediated multidrug resistance | Q93055654 |
| | Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance | Q93089957 |
| | Modulating ROS to overcome multidrug resistance in cancer | Q93341365 |
| | ABCG2-mediated transport of photosensitizers: potential impact on photodynamic therapy | Q95814466 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | chemotherapy | Q974135 |
| P577 | publication date | 2020-02-18 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells | |
| P478 | volume | 12 | |